Please use this identifier to cite or link to this item:
|Title:||Nanomedicine for glaucoma : liposomes provide sustained release of latanoprost in the eye||Authors:||Natarajan, Jayaganesh V.
Wong, Tina T.
Venkatraman, Subbu S.
|Keywords:||DRNTU::Science::Medicine||Issue Date:||2012||Source:||Natarajan, J. V., Ang, M., Darwitan, A., Chattopadhyay, S., Wong, T. T., & Venkatraman, S. S. (2012). Nanomedicine for glaucoma : liposomes provide sustained release of latanoprost in the eye. International journal of nanomedicine, 2012(7), 123-131.||Series/Report no.:||International journal of nanomedicine||Abstract:||Purpose: To report the development and therapeutic evaluation of a liposomal nanocarrier for sustained release of latanoprost, in the rabbit eye. Methods: We fabricated latanoprost-loaded egg-phosphatidylcholine (EggPC) liposomes using the film hydration technique. The delivery vehicles were nano-sized (Z avg = 109 ± 18 nm), had a narrow poly dispersity index (PDI = 0.19 ± 0.04), and a very high loading efficiency (94% ± 5%). Based on in vitro data, we evaluated this formulation for lowering intraocular pressure (IOP) in rabbit eyes. Following a single subconjunctival injection of the latanoprost loaded formulation, the eyes were clinically monitored and the IOP recorded. Results: Latanoprost-loaded EggPC liposomes demonstrated a high drug/lipid mole ratio of 0.181, remained stable for at least 6 months on storage (4°C), and at least 1 month at 25°C. A slow and sustained release of 60% of latanoprost was achieved by 14 days in the in vitro release study. The same formulation demonstrated a greater sustained IOP lowering effect compared with daily administration of topical latanoprost beyond 90 days (4.8 ± 1.5 vs 2.5 ± 0.9 mmHg; P < 0.001). No signs of inflammation were evident in the eyes from slit-lamp examination analysis. Conclusion: The loading required for a long-term sustained delivery of latanoprost for up to 90 days in the rabbit eyes was achieved with EggPC liposomes. A single injection of latanoprost-loaded EggPC liposomes can lower the IOP for up to 90 days, with a greater IOP lowering effect than daily topical administration of latanoprost.||URI:||https://hdl.handle.net/10356/106230
|URL:||http://www.dovepress.com/nanomedicine-for-glaucoma-liposomes-provide-sustained-release-of-latan-peer-reviewed-article-IJN||ISSN:||1176-9114||Rights:||© 2012 Natarajan et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.||Fulltext Permission:||open||Fulltext Availability:||With Fulltext|
|Appears in Collections:||MSE Journal Articles|
Files in This Item:
|IJN-25468-nanomedicine-for-glaucoma--liposomes-provide-sustained-relea_010412.pdf||523.83 kB||Adobe PDF|
Page view(s) 20447
Updated on Jun 14, 2021
Updated on Jun 14, 2021
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.